News Column

United States : ST. LOUIS based CULTIVATION CAPITAL announces $500,000 investment in MSI

August 20, 2014

St. Louis powerhouse Cultivation Capital declared that they will be spending $500,000 in Molecular Sensing, Inc. (MSI). The life sciences firm is commercializing an industry changing solution for drug discovery, which attracted the attention of Cultivation Capital.

MSI has designed a new technique called backscattering interferometry (BSI) that is based on the principle that light slows down and scatters in solution when drug molecules interact with drug aims. New drug development discovers new molecules that interact with the aim in the body that usually functions abnormally when diseased.

By shooting a laser through a sample and measuring how the light scatters after passing through it, MSI can determine molecular binding between a new drug candidate and the target molecule. Dr. William Rich, CEO of MSI, sees the tremendous applications capacity for effeciently transforming drug discovery.

We are working towards accelerating drug development projects by providing the best technology to characterize drug interactions with complex targets quickly and cost effectively , says Dr. Rich.

Cultivation Capital sees serious opportunity in this investment. MSI leverages its advances in the biotech sphere to strengthen their business strategy, says Cultivation Capital General Partner Rick Ryan. They offer drug discovery services to pharmaceutical companies, and soon they will begin shipping their BSI technology directly.

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: TendersInfo (India)

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters